Denosumab: An antifracture therapy for postmenopausal women with osteoporosis

Menopause

Volumn 20, Issue 2, 2013, Pages 117-119

  Jiang, Xuezhi ^a   Schnatz, Peter F ^a,b  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DENOSUMAB;

APPENDICITIS; BONE DENSITY; CELLULITIS; CLINICAL TRIAL (TOPIC); DIVERTICULITIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FRAGILITY FRACTURE; HIGH RISK POPULATION; HUMAN; INFECTION; LABYRINTHITIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PNEUMONIA; POSTMENOPAUSE; REVIEW; WRIST FRACTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RADIUS; RANK LIGAND;

EID: 84873411605     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31827c44bd     Document Type: Review

References (25)

1. National Osteoporosis Foundation. Fast facts of osteoporosis. Available at: http://www/nof.org/node/40. Accessed October 1, 2012.
2. Nayak S, Roberts MS, Greenspan SL. Factors Associated with osteoporosis screening and recommendations for osteoporosis screening in older adults. J Gen Intern Med 2009;24:585-591.
3. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180(Suppl 5):S18-S22.
4. Schnatz PF, Marakovits KA, DuBois M, O'Sullivan DM. Osteoporosis screening and treatment guidelines: are they being followed? Menopause 2011;18:1072-1078.
5. Christenson E, Jiang X, Kagan R, Schnatz PF. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012;64:181-194.
6. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287.
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008.
8. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
9. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-161.
10. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831.
11. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157.
12. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841.
13. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J Bone Miner Res 2011;26:S20.
14. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701.
15. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72-81.
16. Orwoll E, Teglbj&rg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97:3161-3169.
17. Oaks T. FDA approves new indication for ProliaA (denosumab) for the treatment of bone loss in men with osteoporosis at high risk for fracture. Available at: http://www.prnewswire.com/news-releases/fda-approvesnew- indication-for-prolia-denosumab-for-the-treatment-of-bone-loss-inmen-with- osteoporosis-at-high-risk-for-fracture-170581296.html. Accessed October 5, 2012.
18. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int 2006;17: 1726-1733.
19. Simon JA, Recknor C, Moffett AH, Adachi JD, Franek E, Lewiecki M, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 2013;20:130-137.
20. Jancin B. Denosumab shows favorable results in FREEDOM extension. Available at: http://www.familypracticenews.com/news/diabetes- endocrinologymetabolism/single-article/denosumab-shows-favorable-results-in- freedomextension/fc41eecba4638d2aef71f3c7fc8e9a50.html. Accessed October 5, 2012.
21. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222-229.
22. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-4424.
23. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
24. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882.
25. Highlights of prescribing information, Prolia (denosumab). Available at: www.pi.amgen.com/united-states/prolia/prolia-pi.pdf. Accessed October 5, 2012.